Aclaris Therapeutics, Inc. - Common Stock (ACRS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ACRS on Nasdaq
Shares outstanding
108,074,661
Price per share
$3.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
85,675,311
Total reported value
$162,782,120
% of total 13F portfolios
0%
Share change
-6,186,333
Value change
-$11,317,612
Number of holders
103
Price from insider filings
$3.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock (ACRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 13% $21,802,500 14,250,000 BML Investment Partners, L.P. 31 Dec 2024
Bonita Biotech (HK) Ltd 9.4% $33,944,003 11,281,950 Biosion, Inc. 09 Dec 2025
BlackRock, Inc. 6.2% +22% $20,164,873 +$3,698,306 6,700,629 +22% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 6.2% +31% $9,460,129 +$2,402,369 6,662,063 +34% The Vanguard Group 30 Jun 2025
Adage Capital Management, L.P. 4.9% -34% $10,028,474 -$5,554,080 5,278,144 -36% Adage Capital Management, L.P. 30 Sep 2025
Rock Springs Capital Management LP 4.7% $7,720,853 5,046,309 Rock Springs Capital Management LP 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5,449,080 -$2,422,176 3,837,380 -31% Millennium Management LLC 30 Jun 2025

As of 30 Sep 2025, 103 institutional investors reported holding 85,675,311 shares of Aclaris Therapeutics, Inc. - Common Stock (ACRS). This represents 79% of the company’s total 108,074,661 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 13% 14,250,000 0% 25% $27,075,000
Vivo Capital, LLC 8.2% 8,888,888 0% 1.4% $16,888,887
VANGUARD GROUP INC 6% 6,515,458 -2.2% 0% $12,379,370
BlackRock, Inc. 5.3% 5,691,352 +3.2% 0% $10,813,569
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.9% 5,278,144 -45% 0.02% $10,028,474
Rock Springs Capital Management LP 4.3% 4,609,309 -3.4% 0.51% $8,757,687
MORGAN STANLEY 3.8% 4,077,246 +15% 0% $7,746,768
Decheng Capital LLC 3.7% 4,041,736 0% 1.3% $7,679,298
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,389,531 -3.1% 0% $4,541,475
D. E. Shaw & Co., Inc. 2.2% 2,373,226 -15% 0% $4,509,129
ACADIAN ASSET MANAGEMENT LLC 2.2% 2,327,019 -4.4% 0.01% $4,417,000
MARSHALL WACE, LLP 1.6% 1,718,130 -25% 0% $3,264,447
RENAISSANCE TECHNOLOGIES LLC 1.5% 1,619,731 +11% 0% $3,077,489
Palo Alto Investors LP 1.4% 1,566,840 +13% 0.55% $2,976,996
MILLENNIUM MANAGEMENT LLC 1.4% 1,554,458 -59% 0% $2,953,470
Logos Global Management LP 1.4% 1,500,000 -19% 0.28% $2,850,000
CITADEL ADVISORS LLC 1.3% 1,432,677 +25% 0% $2,722,086
AMERIPRISE FINANCIAL INC 1.2% 1,277,817 0% $2,427,852
Bollard Group LLC 1.1% 1,225,476 -9.4% 0.06% $2,328,000
STATE STREET CORP 1% 1,113,146 +11% 0% $2,114,977
Connor, Clark & Lunn Investment Management Ltd. 0.99% 1,067,656 +34% 0.01% $2,028,546
Aldebaran Capital, LLC 0.91% 987,698 -0.6% 1.7% $1,876,626
GOLDMAN SACHS GROUP INC 0.88% 956,051 +511% 0% $1,816,497
DEUTSCHE BANK AG\ 0.85% 923,313 -8.3% 0% $1,754,295
JPMORGAN CHASE & CO 0.7% 758,576 +22% 0% $1,441,294

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 188,760 $567,378 -$18,963 $3.01 6
2025 Q3 85,675,311 $162,782,120 -$11,317,612 $1.90 103
2025 Q2 91,862,480 $130,443,350 -$2,093,251 $1.42 95
2025 Q1 92,164,636 $141,009,418 +$2,108,864 $1.53 106
2024 Q4 87,478,919 $216,988,373 +$93,728,957 $2.48 97
2024 Q3 50,891,008 $58,523,068 -$1,742,222 $1.15 76
2024 Q2 52,848,132 $58,129,308 -$1,619,597 $1.10 93
2024 Q1 54,386,842 $67,436,941 -$3,788,067 $1.24 93
2023 Q4 58,449,543 $61,369,526 -$207,123,774 $1.05 102
2023 Q3 70,071,814 $479,974,125 -$28,113,579 $6.85 137
2023 Q2 71,014,841 $736,442,996 +$5,835,766 $10.37 131
2023 Q1 71,610,627 $579,302,266 +$19,605,105 $8.09 148
2022 Q4 65,900,596 $1,037,946,141 -$2,542,115 $15.75 126
2022 Q3 63,675,444 $1,002,225,041 +$5,530,098 $15.74 124
2022 Q2 63,269,555 $883,318,693 +$55,162,166 $13.96 112
2022 Q1 59,295,213 $1,021,908,185 +$59,352,437 $17.24 107
2021 Q4 56,045,310 $814,890,981 -$39,784,690 $14.54 133
2021 Q3 56,785,960 $1,022,155,424 +$15,328,009 $18.00 126
2021 Q2 56,004,936 $983,410,407 +$20,628,850 $17.56 128
2021 Q1 45,417,666 $1,298,594,000 +$509,363,836 $25.20 95
2020 Q4 31,934,018 $206,591,000 +$27,717,112 $6.47 79
2020 Q3 25,553,008 $65,673,000 -$3,889,513 $2.57 52
2020 Q2 28,456,883 $46,099,261 -$5,512,533 $1.62 56
2020 Q1 32,079,500 $33,361,056 +$3,161,589 $1.04 65
2019 Q4 30,811,789 $58,227,600 +$3,325,295 $1.89 72
2019 Q3 29,070,550 $31,395,961 -$19,214,772 $1.08 76
2019 Q2 35,610,940 $77,957,966 -$16,270,841 $2.19 82
2019 Q1 37,867,320 $227,075,061 -$11,074,522 $5.99 91
2018 Q4 39,079,487 $288,764,092 +$36,606,178 $7.39 95
2018 Q3 29,659,351 $430,705,323 -$29,549,131 $14.52 81
2018 Q2 30,998,695 $618,964,700 +$11,707,281 $19.97 92
2018 Q1 30,570,960 $535,621,157 +$33,812,143 $17.52 100
2017 Q4 28,517,743 $703,264,074 -$10,560,834 $24.66 102
2017 Q3 28,502,689 $696,914,157 +$73,632,695 $25.81 102
2017 Q2 25,609,895 $694,432,125 +$43,716,393 $27.12 101
2017 Q1 23,711,078 $707,195,746 +$74,703,828 $29.82 111
2016 Q4 21,351,804 $579,490,455 +$95,769,317 $27.14 100
2016 Q3 15,510,238 $397,182,894 +$4,351,904 $25.61 59
2016 Q2 15,355,135 $283,613,231 +$13,304,019 $18.47 47
2016 Q1 14,605,233 $276,749,000 +$2,035,314 $18.95 34
2015 Q4 10,288,500 $277,169,982 +$277,169,982 $26.94 33